Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration-Reference-Cited by-同舟云学术

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Published:2022-10 Issue: Volume:56 Page:152081
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Ørnbjerg Lykke M.,Linde Louise^ORCID,Georgiadis Stylianos,Rasmussen Simon H.,Lindström Ulf,Askling Johan,Michelsen Brigitte,Giuseppe Daniela Di,Wallman Johan K.,Pavelka Karel,Závada Jakub,Nissen Michael J.,Jones Gareth T.,Relas Heikki,Pirilä Laura,Tomšič Matija,Rotar Ziga,Geirsson Arni Jon,Gudbjornsson Bjorn,Kristianslund Eirik K.,van sder Horst-Bruinsma Irene,Loft Anne Gitte,Laas Karin,Iannone Florenzo,Corrado Addolorata,Ciurea Adrian,Santos Maria J.,Santos Helena,Codreanu Catalin,Akkoc Nurullah,Gunduz Ozgul S.,Glintborg Bente,Østergaard Mikkel,Hetland Merete Lund

Funder

Novartis Pharma AG

Novartis

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference36 articles.

1. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis;Van Der Heijde;Ann Rheum Dis,2017

2. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force;Smolen;Ann Rheum Dis,2014

3. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration;Ørnbjerg;Ann Rheum Dis,2019

4. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry;Glintborg;Ann Rheum Dis,2010

5. Predicting the outcome of ankylosing spondylitis therapy;Vastesaeger;Ann Rheum Dis,2011

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unmet needs in axial spondyloarthritis. Proceedings of the French spondyloarthritis taskforce workshop;Joint Bone Spine;2024-12

2. The failure of biological treatment in axial spondyloarthritis is linked to the factors related to increased intestinal permeability and dysbiosis: prospective observational cohort study;Rheumatology International;2024-05-14

3. Initial C-reactive protein level: Discriminating between anti-TNF and anti-IL-17 agents as the first biologic treatment for axial spondyloarthritis?;Joint Bone Spine;2024-05

4. Le niveau initial de protéine C réactive : un élément de choix discriminant entre anti-TNF et anti-IL17 en premier traitement biologique ciblé de la spondyloarthrite axiale ?;Revue du Rhumatisme;2023-12

5. Interaction effects of significant risk factors on low bone mineral density in ankylosing spondylitis;PeerJ;2023-11-22